Koken Ltd. AI Stock Analysis
Want to see JP:7963 full AI Analyst Report?
Koken Ltd. (7963) AI Stock Analysis
Koken Ltd.
(TSE/TYO:7963)
Koken Ltd. earns a moderate score. Fundamentals are the main driver: improving revenue growth, recovering margins and a conservative, de-leveraging balance sheet are offset by a sharp deterioration in cash generation, with free cash flow turning negative. Valuation is supportive, with a low 9.5x P/E, a near 3% dividend yield and low beta, offering downside cushion. The main drag is technical weakness, as the stock trades below all major moving averages with negative MACD momentum, though extremely oversold RSI and Stochastic readings suggest the selling may be stretched.
Koken Ltd. (7963) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.94B
- Dividend Yield
- 3.05%
- Average Volume (3M)
- 4,331
- Price to Earnings (P/E)
- 9.7
- Beta (1Y)
- 0.36
- Revenue Growth
- 8.56%
- EPS Growth
- 7.14%
- Country
- Japan
- Employees
- 312
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Koken Ltd. Business Overview & Revenue Model
Company Description
Koken Ltd., along with its subsidiaries, specializes in the production and sale of personal protective equipment for occupational use and products designed to enhance environmental quality throughout Japan. The company organizes its diverse operation...
How the Company Makes Money
null
Koken Ltd. Financial Statement Overview
Summary
Koken Ltd. shows a mixed but generally stable fundamental profile. Revenue grew 7.2% in fiscal 2025, net margin improved to 7.5% and EBIT margin expanded to 10.7%, while the balance sheet strengthened with equity rising to ¥13.8 billion and debt-to-equity falling to 0.42. However, cash flow is a clear weakness: operating cash flow collapsed to ¥136 million and free cash flow turned negative at -¥232 million, meaning earnings are not converting into cash. Modest ROE of 6.4% and margins still below 2022 peaks also temper the score.
Income Statement
68PositiveBalance Sheet
72PositiveCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.14B | 11.86B | 10.76B | 10.59B | 10.60B | 10.20B |
| Gross Profit | 5.43B | 5.38B | 4.92B | 4.84B | 4.99B | 4.65B |
| EBITDA | 1.59B | 1.70B | 1.49B | 1.51B | 1.80B | 1.88B |
| Net Income | 824.49M | 885.29M | 722.06M | 701.13M | 833.11M | 862.37M |
Balance Sheet | ||||||
| Total Assets | 21.79B | 22.44B | 20.95B | 20.87B | 20.62B | 19.64B |
| Cash, Cash Equivalents and Short-Term Investments | 2.92B | 2.68B | 2.53B | 2.98B | 2.39B | 2.19B |
| Total Debt | 5.75B | 5.79B | 5.18B | 6.05B | 6.13B | 6.13B |
| Total Liabilities | 7.93B | 8.65B | 7.91B | 8.52B | 8.80B | 8.52B |
| Stockholders Equity | 13.86B | 13.80B | 13.04B | 12.35B | 11.82B | 11.11B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -232.16M | 445.38M | 886.94M | 451.74M | 417.31M |
| Operating Cash Flow | 0 | 136.14M | 666.37M | 1.08B | 618.95M | 655.48M |
| Investing Cash Flow | 0 | -379.51M | -98.81M | -206.25M | -184.20M | 147.58M |
| Financing Cash Flow | 0 | 370.84M | -1.05B | -307.82M | -291.98M | -176.25M |
Koken Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7963, the sentiment is Negative. The current price of 1640.00 is below the 20-day moving average (MA) of 1676.85, below the 50-day MA of 1749.72, and below the 200-day MA of 1836.15, indicating a bearish trend. The MACD of -30.19 indicates Negative momentum. The RSI at 32.41 is Neutral, neither overbought nor oversold. The STOCH value of 62.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7963.
Koken Ltd. Peers Comparison
Overall Rating
JP:667882Outperform
JP:682375.3Outperform
JP:518762Neutral
JP:652361Neutral
JP:796361Neutral
JP:760045Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | JPY 18.05B | 12.11 | ― | 6.09% | 17.11% | 23.02% | |
| 75Outperform | JPY 33.31B | 9.59 | ― | 3.52% | 2.48% | 11.44% | |
| 62Neutral | JPY 9.86B | 25.40 | ― | 4.43% | 3.38% | -52.61% | |
| 61Neutral | JPY 157.38B | 10.91 | 8.71% | 3.40% | 2.74% | 145.33% | |
| 61Neutral | JPY 8.06B | 9.74 | ― | 3.05% | 8.56% | 7.14% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | JPY 6.87B | -4.42 | ― | 6.51% | -8.68% | -75.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7963 | Koken Ltd. | 1640.00 | -181.11 | -9.95% | |
| JP:6523 | PHC Holdings Corp. | 1236.00 | 278.26 | 29.05% | |
| JP:5187 | Create Medic Co., Ltd. | 1084.00 | 118.68 | 12.29% | |
| JP:6678 | Techno Medica Co., Ltd. | 2118.00 | 234.98 | 12.48% | |
| JP:6823 | Rion Co., Ltd. | 2700.00 | 249.28 | 10.17% | |
| JP:7600 | Japan Medical Dynamic Marketing, Inc. | 261.00 | -205.88 | -44.10% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026